What can the conect4children Stichting (c4c-S) do for ERNs

Published by

C4C Clinical Research Network European Reference Network Network Orphan Drug paediatric Rare Disease Research and Drug Development

conect4children Stichting (c4c-S) is a non-profit, pan-European organisation that supports paediatric clinical research by providing expert advice and trial support services, including feasibility assessments and site identification, for ERNs and other stakeholders. Building on a successful public–private partnership, it mobilises a large network of experts and research-ready sites to improve the efficiency and quality of paediatric trials across Europe.

View this resource Bookmark this resource

EC_Joint Evaluation of the Orphan and Paediatric Regulations_2020

Published by European Commission (EC)

Drug Surveillance Drugs Classification Generic Drug Innovation Market Approval Medical Research Orphan Disease Orphan Drug Paediatrics Therapeutics

This document is a joint evaluation on orphan medicinal products

View this resource Bookmark this resource

Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives

Published by IACMHR Co., Ltd.

Orphan Drug Regulatory Science

This paper describes the current status of the regulation of rare diseases and orphan drugs in Asia and we comparatively analyze the regulation of rare diseases and orphan drugs worldwide in order to examine the challenges to and future perspectives on promoting research on rare diseases and development of orphan drugs in China and other Asian countries.

View this resource Bookmark this resource

Single Patient Expanded Access

Published by IRDiRC

Early Access Support Orphan Drug Orphan Medicine Regulatory Affairs Research and Drug Development Single Patient Expanded Accesss

This FDA program allows early access to drugs and medical devices before marketing approval, under regulatory oversight with collection of Safety data, to individual patients with serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives. This includes emergency and non-emergency expanded access.

View this resource Bookmark this resource

US Expanded Access Program

Published by IRDiRC

Early Access Support Expanded Accesss Programme Orphan Drug Orphan Medicine Regulatory Affairs Research and Drug Development

The Program allows patients with serious rare diseases to have access to pre-market drugs and devices, if the Sponsor agrees to this under their expanded access policy

View this resource Bookmark this resource

NIH funded programs and resources

Published by IRDiRC

Funded Programme NIH Initiative Orphan Drug Public Research and Drug Development

NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability. The tool has its best use at very early phases of drug development

View this resource Bookmark this resource

European Network of Paediatric Research at the European Medicines Agency

Published by IRDiRC

Early Access Support European Network of Paediatric Research Orphan Drug Paediatric Medicine Regulatory Affairs Research and Drug Development

The European Network of Paediatric Research at the European Medicines Agency (Enpr- EMA) is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children. Enpr-EMA enables networking and collaboration with members from within and outside the European Union (EU), including academia and the pharmaceutical industry

View this resource Bookmark this resource

EU Compassionate Use Programs

Published by IRDiRC

Clinical Development Compassionate Use Early Access Support EMA Compassionate Use European Union Orphan Drug Regulatory Affairs Research and Drug Development

Compassionate use is a treatment option that allows the use of an unauthorised medicine. Under strict conditions, products in development can be made available to groups of patients who have a disease with no satisfactory authorised therapies and who cannot enter clinical trials.

View this resource Bookmark this resource

Sakigake Designation System

Published by IRDiRC

Early Access Support Japan MHLW or PMDA Regulatory Orphan Drug Regulatory Affairs Sakigake

SAKIGAKE aims at shortening premarket review period for innovative new medical products that satisfy certain criteria, such as severity of intended indication, by designating such products during the early stages of development, and providing prioritized consultation services and premarket pharmaceutical affairs review.

View this resource Bookmark this resource

Ethic’s Committees assessment of protocols for trials with orphan medications

Published by IRDiRC

Ethic and Legal Issue Guideline Ethical Assessment Orphan Drug Protocol Assessment Regulatory Sciences

Ethical assessment of clinical trials in orphan diseases should be done by experienced committees, and should ensure that all relevant aspects of this particular type of trials is properly assessed.

View this resource Bookmark this resource

The Innovation Management Toolbox was originally developed through funding from the EJP RD project, which received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825575. The continued development and maintenance of the Toolbox are now supported by the ERDERA partnership, funded under the European Union’s Horizon Europe Research & Innovation programme, grant agreement No. 101156595.

IMT Feedback

Did the IMT help you in finding the resource you needed?